StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Valuable Information

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Apr 13, 2021 10:31am

107 Views

Post# 32984555

RE:RE:RE:Valuable Information

Bully88 wrote:
Once we get more clarification and information we should see our SP normalise.

They made this aquisition for 15,000,000 shares up front and then 8,000,000 more over time based on performance.

so just using the 15 mil shares up front, with the amount of shares outstanding already, adding 15 million shares roughly makes our shares 23% less valuable then the 1.50 SP when this aquisition was made. Making our shares "value" roughly 1.25 which coincides with the new analyst target price.

different calculations once we use the 8 million more shares but since they are based on performance over time, by then we will know how profitable we are and have a more clear view of our fundamentals and we can discuss more at that point.

Again, once we get more clarification and update on this aquisition and AVRT program, we "should" see share price normalise.

all speculative and rough calculations, and of course, just my opinion.

Your numbers look about right to me. Tripp simply needs to adapt a program of more frequent NRs in order to keep investors in sync with corporate. Many companies put out regular NRs simply on operational updates, confirmation of status, insight to the upcoming quarterly results etc. The net effect is that investors feel they are in touch and up to date - this is what is needed here as the sp generally reacts to NRs.